argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, a robust pipeline with significant growth potential, and strategic expansions. Positive clinical data and label expansions for VYVGART, along with a growing addressable market, are promising. While management was unclear on some specifics, the overall sentiment remains positive due to the company's strategic initiatives and expected growth across multiple fronts.
Key Financial Performance
Product net sales (Q4 2025) $1.3 billion, representing a year-over-year growth of 90%. This growth was driven by solid patient demand and prescriber confidence, particularly due to the launch of the prefilled syringe for self-injection.
Product net sales (Full year 2025) $4.2 billion, representing a year-over-year growth of 90%. The growth was attributed to strong patient demand and the successful launch of the prefilled syringe.
Regional breakdown of product revenue (Q4 2025) $1.1 billion in the U.S. (68% growth from Q4 of the prior year), $63 million in Japan, $110 million in the rest of the world, and $26 million in product supplied to Zai Lab in China. The U.S. growth was driven by solid patient demand and prescriber confidence.
Total operating expenses (Q4 2025) $955 million, an increase of $149 million compared to the third quarter. This increase was due to higher R&D and SG&A expenses to support revenue growth and pipeline execution.
Cost of sales (Q4 2025) $150 million, with a year-to-date gross margin consistent at 11%.
Combined R&D and SG&A expenses (Full year 2025) $2.7 billion, in line with financial guidance. The expenses reflect the company's commitment to pipeline execution and market expansion.
Operating profit (Q4 2025) $367 million, contributing to $1.1 billion for the full year. This marks the first year of annual operating profitability for the company.
Profit (Q4 2025) $533 million, contributing to $1.3 billion for the full year. This was supported by nonrecurring tax items and favorable foreign exchange movements.
Cash balance (End of Q4 2025) $4.4 billion, representing a more than $1 billion increase over the year. This increase reflects the company's strong financial performance and ability to invest in growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYVGART Hytrulo: Successful launch of prefilled syringe for self-injection, reaching 19,000 patients globally. Demonstrated significant improvement in MGII patient-reported ocular score in Phase III ADAPT OCULUS study for ocular MG.
ARGX-213 and ARGX-124: Advancing as next-generation FcRn assets, with focus on combination approaches and new delivery modalities.
Empasiprubart: Upcoming Q4 readout for MMN, aiming to extend neurology footprint with a first-in-class C2 inhibitor.
MG and CIDP: VYVGART is the fastest-growing and #1 prescribed biologic in MG, with significant adoption in CIDP. Expansion into seronegative and ocular MG expected to add 18,000 patients.
Autoimmune myositis and Sjogren's disease: Broadening VYVGART's footprint into rheumatology, addressing unmet needs in IMNM with an estimated 20,000 patients.
Financial Performance: Achieved $4.2 billion in product net sales for 2025, marking a 90% year-over-year growth. Operating profit reached $1.1 billion, with a cash balance of $4.4 billion.
Prefilled Syringe (PFS): Key driver of increased VYVGART demand, with over 4,700 prescribers and expanded access through UnitedHealthcare.
Vision 2030: Strategic priorities include broader patient adoption, label expansion, and advancing FcRn medicines with next-generation molecules and delivery modalities.
Pipeline Development: Focus on progressing first-in-class molecules like ARGX-121 and ARGX-118, and advancing three Phase I programs in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company plans to file an sBLA with the FDA for ocular MG based on the Phase III ADAPT OCULUS study results. Regulatory approval processes can be lengthy and uncertain, posing a risk to the timely expansion of their product label.
Market competition: VYVGART is the fastest-growing biologic in MG, but competitive pressures from other biologics and treatments could impact its market share and growth trajectory.
Supply chain and operational costs: Operating expenses are expected to grow significantly in 2026 to support revenue growth and pipeline execution. This could strain financial resources if revenue growth does not meet expectations.
Economic uncertainties: The company’s financial performance is subject to economic conditions, including foreign exchange movements, which have previously impacted tax benefits.
Strategic execution risks: The company is pursuing multiple avenues for expansion, including new indications and pipeline candidates. Failure to execute on these strategies could hinder long-term growth and market leadership.
Unmet medical needs and patient adoption: While the company is addressing unmet needs in diseases like IMNM and MMN, the success of these efforts depends on patient adoption and the ability to demonstrate clear clinical benefits.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Priorities for 2026: The company aims to impact more patients globally with VYVGART through broader patient adoption and label expansion. It is focusing on shaping the future of FcRn medicines with next-generation molecules, delivery modalities, and combination approaches. Additionally, it plans to deliver the next wave of immunology innovation, supported by a strong late-stage portfolio and a goal of at least one new pipeline candidate per year.
VYVGART Expansion: The company plans to expand VYVGART's reach to patients with seronegative MG and ocular MG, targeting a total addressable population of approximately 60,000 patients in the U.S. The seronegative MG PDUFA date is May 10, and the company plans to file an sBLA for ocular MG based on positive Phase III ADAPT OCULUS study results.
CIDP Market Expansion: The company is focusing on expanding the CIDP market beyond the initial 12,000 addressable patient population. Efforts include evidence generation, patient activation, and new prescriber adoption. The prefilled syringe is expected to drive uptake, and a biomarker program is being developed to better define responders and unlock earlier and broader use.
Pipeline Development: The company is advancing two next-generation assets, ARGX-213 and ARGX-124, and investing in efgartigimod-anchored combination approaches and new delivery modalities. It expects to progress three Phase I programs in 2026, including a program from its Tensegrity collaboration.
Autoimmune Myositis and Sjogren's Disease: The company is exploring expansion into autoimmune myositis and Sjogren's disease, broadening VYVGART's footprint into rheumatology. The work in IMNM addresses a significant unmet need with an estimated 20,000 patients and no approved treatment options.
Empasiprubart in MMN: The company plans a Q4 readout for empasiprubart in MMN, positioning it to advance a second medicine to patients and extend its neurology footprint with a first-in-class C2 inhibitor.
Financial Guidance for 2026: Operating expenses are expected to grow at a similar percentage as in prior years, with SG&A growth supporting revenue growth in current markets and expansion into new patient populations. R&D expenses will increase to support pipeline execution. The effective tax rate is expected to remain in the low to mid-teens.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the average price for VYVGART's new subindications (seronegative and ocular MG), and what proportion of patients are likely to seek this treatment?
A:The average price for VYVGART's new subindications is expected to be similar to MG at $225,000 net price. The addressable market expands by 11,000 patients for seronegative and 7,000 for ocular MG, with the latter number representing those eligible for VYVGART based on prior research.
Q:Are you seeing expansion beyond the initial 12,000 CIDP patients targeted, and what impact will broader coverage have on adoption rates?
A:Yes, there is expansion beyond the initial 12,000 patients, with some patients coming directly to VYVGART instead of switching from IVIg. Broader coverage, now over 90% of covered lives, is expected to contribute to steady growth and adoption rates.
Q:Will approval in ocular MG drive more utilization in less advanced MG patients, and is there data to demonstrate prevention of progression to generalized disease?
A:Approval in ocular MG is expected to drive earlier use of biologics in less advanced MG patients. Long-term data collection is planned to assess whether VYVGART delays progression to generalized MG.
Q:Are there any particular considerations for Q1 dynamics?
A:Q1 dynamics include reverifications and winter storms, which may cause a slowdown similar to last year. However, underlying growth dynamics remain strong, supported by new patient starts, prescriber expansion, and label expansions.
Q:What is the efficacy bar for the Phase III myositis trial, and how does it compare to other treatments?
A:The efficacy bar is a statistically significant benefit. For IMNM, any benefit is clinically meaningful due to the lack of approved therapies. Comparisons to other treatments like brepo in DM are difficult, but positive data in these diseases is beneficial for patients.
Q:What is the regulatory strategy for the Graves program, and will a single pivotal study suffice?
A:The regulatory division has requested two trials for the Graves program, which are currently being executed.
Q:How will the auto-injector for VYVGART be positioned versus the prefilled syringe (PFS)?
A:The auto-injector, planned for 2027, will provide a better experience for needle-phobic patients but is not expected to be as significant an innovation as the PFS, which allowed for patient self-administration.
Q:What is the strategy for the next-generation FcRns (124 and 213), and how are indications being selected?
A:The next-generation FcRns aim to provide better patient experiences in existing indications and expand into new indications. Indication strategies are being developed.
Q:What are the growth dynamics for VYVGART through 2026, and how will competition impact its profile?
A:VYVGART is expected to grow across all indications, geographies, and product presentations. Competition is seen as beneficial for market expansion, and VYVGART's strong efficacy, safety, and flexibility are expected to maintain its leadership.
Q:Will the Phase III myositis trial support approval by subgroup, and how do the commercial opportunities differ between subgroups?
A:The trial is designed to make statements on all three subsets, with IMNM being a high-opportunity area due to the lack of approved treatments. DM has more patients but also more competition and heterogeneity.
Q:What are the risks and considerations for the EMPASSION trial in MMN?
A:The trial uses a head-to-head design with grip strength as the primary endpoint, based on robust Phase II data. The non-inferiority margin was determined using grip strength data, and continuous improvement in grip strength gives confidence in meeting or exceeding IVIg outcomes.
Q:What is the timeline for ocular MG to become a contributor to VYVGART's growth?
A:After filing and approval, it typically takes about two quarters to update payer policies and see the impact of the new indication.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or clarity on the following: 1. Specific market data research on the proportion of patients likely to seek VYVGART treatment. 2. Detailed efficacy benchmarks for the myositis trial compared to other treatments. 3. Indication strategies and trial sizes for next-generation FcRns (124 and 213). 4. Detailed data on ocular MG's clinical significance and steroid use balance between trial arms. 5. Specific timelines and data for the Phase I results of ARGX-213.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADAPT OCULUS
FcRn
III ADAPT
MGII patient
OCULUS study
PDUFA
Sandrine
Slide argenx
Today
VYVGART biologics
VYVGART patient
adoption
biology
burden
chapter
clinician
combination approach
delivery modality
diplopia ptosis
evidence
field
focus
footprint
generation
gravis
immunology
market expansion
meeting
path
patient Slide
patient score
placebo
point improvement
science patient
team
therapy patient
today result
treatment option
treatment symptom
ARGX Transcript
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary indicates strong financial performance with a 25% revenue increase and a shift from net loss to net income. Cash reserves are robust at $1.5 billion. Despite increased R&D and operating expenses, the financial health appears stable, supporting growth initiatives. The absence of strategic, operational, and risk updates in the call limits insights, but the positive financial results and cash position suggest a positive market reaction over the next two weeks.
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary and Q&A indicate strong financial performance, a robust pipeline with significant growth potential, and strategic expansions. Positive clinical data and label expansions for VYVGART, along with a growing addressable market, are promising. While management was unclear on some specifics, the overall sentiment remains positive due to the company's strategic initiatives and expected growth across multiple fronts.
ARGX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
